Barama Azemi A
Surgery and Transplantation, University of Montreal, Montreal, Quebec, Canada.
Drugs. 2008;68 Suppl 1:33-9. doi: 10.2165/00003495-200868001-00005.
Proteinuria is a common complication occurring after kidney transplantation. It is associated with an increased risk of renal failure and patient death. Treatment with ACE inhibitors or angiotensin receptor antagonists (blockers) has been shown to reduce proteinuria after kidney transplantation, as well as improve both graft and patient survival. An increase in proteinuria has been observed in some patients after initiation of sirolimus therapy. Although the mechanism of this remains unclear, high proteinuria at baseline and poor renal function at baseline have been identified as potential risk factors for the development of proteinuria after conversion to sirolimus. Initiation of sirolimus therapy is not recommended in patients with early histological indicators of glomerular damage; however, in patients with healthy grafts, sirolimus may prevent future glomerulosclerosis. Early treatment with an ACE inhibitor and sirolimus, prior to the appearance of glomerular changes, may result in better outcomes.
蛋白尿是肾移植后常见的并发症。它与肾衰竭风险增加及患者死亡相关。已证明使用血管紧张素转换酶抑制剂或血管紧张素受体拮抗剂(阻滞剂)治疗可降低肾移植后的蛋白尿,并改善移植物和患者的存活率。在一些患者开始西罗莫司治疗后观察到蛋白尿增加。尽管其机制尚不清楚,但基线时的高蛋白尿和基线时的肾功能不佳已被确定为转换为西罗莫司后发生蛋白尿的潜在危险因素。对于有早期肾小球损伤组织学指标的患者,不建议开始西罗莫司治疗;然而,对于移植物健康的患者,西罗莫司可能预防未来的肾小球硬化。在肾小球变化出现之前,早期使用血管紧张素转换酶抑制剂和西罗莫司治疗可能会带来更好的结果。